Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...